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Summary
Background Randomised trials of vitamin D supplementation for cardiovascular disease and all-cause mortality have 
generally reported null findings. However, generalisability of results to individuals with low vitamin D status is 
unclear. We aimed to characterise dose-response relationships between 25-hydroxyvitamin D (25[OH]D) 
concentrations and risk of coronary heart disease, stroke, and all-cause mortality in observational and Mendelian 
randomisation frameworks.
Methods Observational analyses were undertaken using data from 33 prospective studies comprising 
500 962 individuals with no known history of coronary heart disease or stroke at baseline. Mendelian randomisation 
analyses were performed in four population-based cohort studies (UK Biobank, EPIC-CVD, and two Copenhagen 
population-based studies) comprising 386 406 middle-aged individuals of European ancestries, including 
33 546 people who developed coronary heart disease, 18 166 people who had a stroke, and 27 885 people who died. 
Primary outcomes were coronary heart disease, defined as fatal ischaemic heart disease (International Classification 
of Diseases 10th revision code I20-I25) or non-fatal myocardial infarction (I21-I23); stroke, defined as any 
cerebrovascular disease (I60-I69); and all-cause mortality. 
Findings Observational analyses suggested inverse associations between incident coronary heart disease, stroke, and 
all-cause mortality outcomes with 25(OH)D concentration at low 25(OH)D concentrations. In population-wide 
genetic analyses, there were no associations of genetically-predicted 25(OH)D with coronary heart disease, stroke, or 
all-cause mortality. However, for the participants with vitamin D deficiency (25[OH]D concentration <25 nmol/L), 
genetic analyses provided strong evidence for an inverse association with all-cause mortality (odds ratio [OR] per 
10 nmol/L increase in genetically-predicted 25[OH]D concentration 0·69 [95% CI 0·59–0·80]; p<0·0001) and non-
significant inverse associations for stroke (0·85 [0·70–1·02], p=0·09) and coronary heart disease (0·89 [0·76–1·04]; 
p=0·14). A finer stratification of participants found inverse associations between genetically-predicted 25(OH)D 
concentrations and all-cause mortality up to around 40 nmol/L.
Interpretation Stratified Mendelian randomisation analyses suggest a causal relationship between 25(OH)D 
concentrations and mortality for individuals with low vitamin D status. Our findings have implications for the design 
of vitamin D supplementation trials, and potential disease prevention strategies.
Funding British Heart Foundation, Medical Research Council, National Institute for Health Research, Health Data 
Research UK, Cancer Research UK, and International Agency for Research on Cancer.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 
4.0 license.
Introduction
Vitamin D is an essential nutrient obtained from 
sunlight, dietary intake, and supplementation.1 Obser­
vational epidemiological studies have consistently 
found that low concentrations of circulating 25­hydro x y­
 vitamin D (25[OH]D), a metabolite used as a clinical 
indicator of vitamin D status, are associated with an 
increased risk of cardiovascular disease and all­cause 
mortality, as well as other chronic diseases.2,3 However, 
several large random ised trials of vitamin D supple­
mentation have reported null results,4–6 casting doubt on 
the observational evidence. However, as trials have 
typically recruited partici pants irrespective of baseline 
25(OH)D concentration, they have not been sufficiently 
powered to test supplementation effects in subgroups 
with low 25(OH)D concentrations.7
An efficient approach for assessing the potential causal 
effect of vitamin D supplementation is Mendelian 
randomisation. Mendelian randomisation uses genetic 
variants specifically related to a particular exposure to 
compare genetically­defined population subgroups with 
different average levels of the exposure. The independent 
segregation of alleles at conception means that these 
genetically­defined subgroups should not differ 
systematically with respect to confounding variables, 
creating a natural experiment analogous to a randomised 
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trial.8 Therefore, Mendelian randomisation analyses 
provide more reliable insights into causal relationships 
between risk factors and disease outcomes than 
conventional observational analyses. Previous Mendelian 
randomisation analyses have reported null associations of 
genetically­predicted 25(OH)D concentrations with coro­
nary heart disease9,10 and ischaemic stroke.11,12 An inverse 
association has been observed between genetically­
predicted 25(OH)D and all­cause mortality.13 Null findings 
have been observed for several further outcomes, 
including other cardiovascular diseases and cancers.14
Previous Mendelian randomisation analyses assumed a 
linear dose-response relationship between genetically­
predicted 25(OH)D and cardiovascular disease. However, 
some observational analyses have reported non­linear 
associations,15,16 suggesting methods that assume linearity 
might not provide an accurate picture of the dose-response 
relationship. In this study, we performed the largest 
observational analysis to date to characterise the shape 
of association between 25(OH)D concentrations and 
cardio vascular disease outcomes in an individual 
participant data meta­analysis of 33 prospective studies. 
We then did stratified Mendelian randomisation analyses 
to assess evidence for potential causal effects of 25(OH)D 
concentrations on risk of major cardiovascular disease 
outcomes including coronary heart disease and stroke, all­
cause mortality, and cause­specific mortality for population 
subgroups with different 25(OH)D concentrations.
Methods
Study design and participants
We undertook observational analyses using data from UK 
Biobank, the European Prospective Investigation into 
Cancer and Nutrition Cardiovascular Disease study 
(EPIC­CVD), and 31 studies from the Vitamin D Studies 
Collaboration (VitDSC). Genetic analyses were done 
using data from UK Biobank, EPIC­CVD, and two 
Copenhagen population­based studies.
UK Biobank is a prospective cohort study of around 
500 000 people aged 40 to 69 years at baseline, recruited in 
2006–10 from the UK and followed up for a median of 
10·9 years (IQR 10·1–11·7).17 For observational analyses, 
we analysed 384 721 individuals with a valid 25(OH)D 
measurement and without previous known cardio­
vascular disease at baseline. For genetic analyses, we 
included data on 333 002 unrelated individuals of 
European ancestries with a valid 25(OH)D measurement 
and genetic data that passed quality control steps 
described previously.18 EPIC­CVD is a case­cohort study 
derived from a cohort of over 500 000 individuals recruited 
at 23 centres across 10 European countries.19,20 Participants 
were followed up for a median of 9·5 years (IQR 
6·1–12·6). We analysed 26 336 individuals with a valid 
25(OH)D measurement and without previous known 
cardiovascular disease at baseline in observational 
analyses, and 22 142 individuals of European ancestry in 
genetic analyses with a valid 25(OH)D measurement and 
genetic data that passed quality control steps. VitDSC 
comprises 89 915 participants from 31 mostly population­
based, prospective studies across 11 countries. We 
analysed individual participant data on 25(OH)D 
concentrations, conventional cardiovascular risk factors, 
and major incident cardiovascular morbidity and 
mortality for 67 992 individuals without previously known 
cardiovascular disease. The Copenhagen City Heart Study 
(CCHS) and Copenhagen General Population Study 
Research in context
Evidence before this study
We searched for randomised trials investigating the effects of 
vitamin D supplementation on cardiovascular disease or all-cause 
mortality published in any language from inception up until 
April 16, 2021, in PubMed, Scientific Citation Index Expanded, 
and Embase using the search terms listed in the appendix. An 
example search is (“Cardiovascular Diseases”[MeSH] OR 
“Cardiovascular Disease” OR “All-cause Mortality” OR “Mortality” 
OR “Survival”). However, no study had combined the following 
key features required to achieve reliable estimates of the effect of 
vitamin D supplementation on cardiovascular disease or mortality 
in vitamin D deficient individuals: availability of individual-
participant data on large sample sizes (eg, >1000 individuals with 
25-hydroxyvitamin D [25(OH)D] concentrations of less than 
25 nmol/L) with moderate numbers of cardiovascular disease or 
all-cause mortality events (eg, > 100 events). In summary, large 
randomised controlled trials and mendelian randomisation 
investigations have not been able to show beneficial effects of 
vitamin D supplementation on risk of coronary heart disease, 
stroke, or mortality.
Added value of this study
We characterised dose-response relationships for 25(OH)D, a 
metabolite used as a clinical indicator of vitamin D status, 
with cardiovascular disease and mortality in the largest such 
epidemiological analysis done to date, using statistical 
methods tailored to the investigation of non-linear risk 
factor-disease relationships. Our observational analyses 
indicate threshold relationships between 25(OH)D 
concentrations and risk of both cardiovascular disease and all-
cause mortality. Genetic analyses support a dose-dependent 
inverse causal effect of 25(OH)D concentrations on all-cause 
mortality risk up to a threshold of around 40 nmol/L. 
Estimates for coronary heart disease and stroke risk at low 
25(OH)D concentrations were in the inverse direction, but 
generally non-significant.
Implications of all the available evidence
Taken together, these findings suggest that vitamin D 
supplementation could reduce mortality risk, but only in 
individuals with low 25(OH)D concentrations.
See Online for appendix
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(CGPS) are prospective cohort studies in the Danish 
population.21,22 CCHS was initiated in 1976 and 
participants were followed up periodically until 2018. 
Median follow­up was 21·4 years (IQR 12·3–32·6). CGPS 
was initiated in 2003 and has a median follow­up of 
8·8 years (IQR 8·1–13·6). For genetic analyses, we 
analysed a total of 31 262 individuals from both studies 
with genetic data and a 25(OH)D measurement. For all 
studies, written informed consent was obtained from 
participants and approval was obtained from relevant 
ethics committees.
Procedures
Concentrations of 25(OH)D in blood were measured using 
the Liaison immunoassay analyser (DiaSorin; Saluggia, 
Italy) in the UK Biobank and Copenhagen studies, and 
liquid chromatography­tandem mass spectrometry in the 
EPIC­CVD study. In VitDSC, concentrations were 
measured by radioimmunoassay, direct chromatographic 
approaches, or other immuno assays (appendix p 9). 
Stratification of participants by 25(OH)D concentrations 
was based on guidelines set by the National Institute for 
Health and Care Excellence23 (adequate [>75 nmol/L], 
sufficient [50–75 nmol/L], insufficient [25–49 nmol/L], and 
deficient [<25 nmol/L]). Measurements were seasonally 
adjusted in each study to correspond to a measurement 
taken in autumn by subtracting the study­specific mean 
25(OH)D concentration for the season the measurement 
was taken in and then adding the study­specific mean 
25(OH)D concentration for autumn measurements. In 
EPIC­CVD, centre­specific means were used rather than 
study­specific means.
To minimise potential bias due to horizontal pleiotropy, 
we considered genetic variants from four gene regions 
previously shown to be strongly associated with 25(OH)D 
and implicated in the transport, metabolism, and synthesis 
of vitamin D:24 GC, DHCR7, CYP2R1, and CYP24A1. The 
GC gene encodes vitamin D binding protein. The DHCR7 
gene product converts 7­dehydrocholesterol to cholesterol, 
reducing 7­dehydrocholesterol available for conversion to 
previtamin D3 by solar radiation. The CYP2R1 gene 
encodes vitamin D 25­hydroxylase, a regulator of 25(OH)D 
synthesis through 25­hydroxylation of vitamin D in the 
liver. The CYP24A1 gene product inactivates the active 
form of vitamin D (1α25(OH)2D). To maximise the 
variance explained by the genetic instrument, we 
considered available variants at each genetic locus and 
selected variants associated with 25(OH)D concentrations 
using a stepwise selection method (appendix p 4). For UK 
Biobank and EPIC­CVD, 21 variants were included in the 
analysis (appendix p 11). For the Copenhagen studies, 
because of limited availability of genetic measurements, 
analyses were restricted to three variants: two from the 
CYP2R1 locus (rs12794714 and rs117913124) and one from 
the DHCR7 locus (rs7944926).
We also considered a score based on 71 genetic variants 
from across the genome (referred to as a genome­wide 
score) previously shown to be associated with 25(OH)D 
concentrations at a genome­wide level of statistical 
significance.25
Outcomes
Outcomes were classified using International 
Classification of Diseases, Tenth Revision (ICD­10) 
codes. Primary outcomes were coronary heart disease, 
defined as fatal ischaemic heart disease (ICD­10 code 
I20–I25) or non­fatal myocardial infarction (I21–I23); 
stroke, defined as any cerebrovascular disease (I60–I69); 
and all­cause mortality. We performed secondary 
analyses for cause­specific mortality divided into 
cardiovascular mortality, cancer mortality, or non­
cardiovascular non­cancer mortality using ICD­10 codes 
(appendix p 10). Prespecified observational analyses 
included incident events only. We performed 
supplementary genetic analyses restricted to incident 
coronary heart disease and stroke events, and separating 
ischaemic stroke (I63–I64) and haemorrhagic stroke 
(I60–I61).
Statistical analysis
Observational associations were assessed by inverse­
variance weighted random­effects meta­analysis of study­
specific hazard ratios (HRs), calculated using Cox 
proportional hazards regression models stratified by sex 
and, as appropriate, centre or trial group. Primary 
analyses were adjusted for conventional risk factors, 
namely age at blood draw for 25(OH)D measurement, 
calendar month of blood draw, smoking status (current 
vs other), total cholesterol, HDL cholesterol, systolic 
blood pressure, known history of diabetes, and BMI.
The primary dose-response analyses assessed the 
shape of association between 25(OH)D and outcomes by 
meta­analysis of fractional polynomials adjusted for the 
conventional risk factors. Supplementary analyses 
combined study­specific HRs by tenths of 25(OH)D and 
plotted the pooled HRs against the pooled mean 
25(OH)D within each tenth.
We calculated a genetic risk score weighted by the 
conditional associations of the genetic variants with 
25(OH)D concentration in UK Biobank (appendix p 11). 
Mendelian randomisation estimates were calculated using 
the ratio method by dividing the genetic association with 
the outcome by the genetic association with 25(OH)D 
concentration and scaling the estimate to a 10 nmol/L 
difference in genetically­predicted 25(OH)D concentration. 
Genetic associations were estimated using logistic 
regression for disease outcomes and using linear 
regression for 25(OH)D concentrations. All regression 
models were adjusted for age at baseline, sex, centre (for 
UK Biobank and EPIC­CVD), and ten genetic principal 
components of ancestry. We assessed specificity of the 
genetic risk score by testing its associations with a range of 
cardiovascular risk factors in the UK Biobank study. We 
undertook sensitivity analyses using the UK Biobank data 
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excluding variants from each of the four gene regions in 
turn to check whether results were driven by a single gene 
region.
In addition to analyses performed in the overall study 
sample to estimate population­averaged causal effects, we 
also undertook stratified analyses in strata of the 
population defined according to residual 25(OH)D. 
Residual 25(OH)D was calculated as the residual from 
regression of 25(OH)D on the mean­centred genetic risk 
score. By stratifying on residual 25(OH)D, we compare 
individuals in the population who would have 25(OH)D 
concentrations in the same stratum if they had the same 
genotype. We then calculated Mendelian randomisation 
estimates for each stratum (adequate, sufficient, 
insufficient, and deficient) using the ratio method with the 
genetic risk score as an instrumental variable, and 
combined stratum­specific estimates across studies using 
fixed­effect meta­analysis. We also divided each study 
sample into finer categories at 5 nmol/L intervals and 
meta­analysed stratum­specific ratio estimates to 
investigate any threshold in the potential effect of 
25(OH)D.
Although stratification on residual 25(OH)D rather than 
25(OH)D directly is important to avoid collider bias, 
correlation between residual 25(OH)D and 25(OH)D 
was 0·977. Hence, regarding the interpretation of 
estimates, distinction between stratifying on residual 
25(OH)D and 25(OH)D directly is minimal. All statistical 
analyses were done in R version 3.4.3, Stata/SE 15.1, or 
BOLT­LMM version 2.3.4.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
386 406 participants from the four studies were included 
in genetic analyses (table), including 33 546 people who 
had coronary heart disease, 18 166 people who had a stroke, 
and 27 885 people who died, and 500 962 participants were 
included in observational analyses (appendix pp 12–14). Mean 
age of participants included in the genetic analysis ranged 
from 54·8 years (SD 9·4) to 57·5 years (12·9), with similar 
numbers of men and women in each study, and the mean 
season­shifted 25(OH)D concentrations (corresponding to 
an autumn measurement) were 54·5 nmol/L (SD 19·6) 
in UK Biobank, 46·9 nmol/L (16·4) in EPIC­CVD, and 
53·8 nmol/L (25·9) in the Copenhagen studies. 
12 957 (3·9%) of 333 002 people in the UK Biobank study 
and 1158 (3·7%) of 31 262 people in the Copenhagen 
studies were in the deficient category, compared with 
1522 (6·9%) of 22 142 people in EPIC­CVD (appendix 
p 15). Mean 25(OH)D estimates did not notably differ by 
assay type (appendix p 24). The focused genetic risk score 
explained 4·7% of the variance in 25(OH)D concentrations 
in UK Biobank study, 5·8% in EPIC­CVD, and 1·8% in 
the Copenhagen studies (appendix p 25). This genetic risk 
score was not associated with a range of cardiovascular 
risk factors in UK Biobank, except for BMI and HDL 
cholesterol, although these associations were small 
(appendix p 26). The genome­wide score was strongly 
associated with LDL cholesterol and triglycerides 
(appendix p 27), and so Mendelian randomisation 
estimates using this score are unreliable.
Observational associations had a similar non­linear 
shape for all outcomes (figure 1; appendix p 28): at low 
concentrations of 25(OH)D, there was an inverse 
association with all outcomes, whereas at higher 
concentrations of 25(OH)D, the association was null for 
cardiovascular mortality and weakly positive for other 
mortality outcomes. For coronary heart disease and stroke, 
there was no strong association with 25(OH)D con­
centrations above 50 nmol/L, but a progressively steeper 
association was observed below this threshold. For all­
cause mortality, in comparison to other outcomes, the 
strength of the inverse association at lower 25(OH)D 
concentrations was stronger and began at a higher 
25(OH)D concentration.
The shapes of the observational associations in the 







Age at baseline, years 57·1 (8·1) 54·8 (9·4) 57·5 (12·9)
Sex
Female 177 733 (53·4) 11 426 (51·6) 17 311 (55·4)
Male 155 269 (46·6) 10 716 (48·4) 13 951 (44·6)
25(OH)D concentration, nmol/L 54·5 (19·6) 46·9 (16·4) 53·8 (25·9)
Residual 25(OH)D strata*
Deficient (<25 nmol/L) 12 957 (3·9%) 1522 (6·9%) 1158 (3·7%)
Insufficient (25–49 nmol/L) 133 922 (40·2%) 11 845 (53·5%) 9730 (31·1%)
Sufficient (50–74 nmol/L) 138 605 (41·6%) 7717 (34·9%) 12 375 (39·6%)
Adequate (≥75 nmol/L) 47 518 (14·3%) 1058 (4·8%) 7999 (25·6%)
Coronary heart disease events 22 363 (6·7%) 5942 (26·8%) 5241 (16·8%)
Stroke events 10 489 (3·1%) 5478 (24·7%) 2199 (7·0%)
Deaths 20 340 (6·1%) N/A† 7545 (24·1%)
BMI (kg/m²) 27·3 (4·8) 26·7 (4·3) 25·9 (4·2)
SBP (mm Hg) 137·5 (18·6) 137·4 (21·3) 140·1 (21·0)
Smoking‡
Current 34 085 (10·2%) 6867 (31·0%) 8387 (26·9%) 
Other 298 940 (89·8%) 15 275 (69·0%) 22 784 (73·1%)
Diabetes
Known history 15 822 (4·8%) 1234 (5·6%) 1244 (4·0%)
No known history 317 203 (95·2%) 20 908 (94·4%) 30 018 (96·0%)
Data are mean (SD) for continuous variables or N (%) for categorical variables. 25(OH)D concentrations are season-shifted 
to correspond to a measurement taken in autumn. 25(OH)D=25-hydroxyvitamin D.  CHD=coronary heart disease. 
SBP=systolic blood pressure. *Stratification of participants into categories of 25(OH)D concentrations was done using 
season-shifted measurements based on guidelines set by the UK National Institute for Health and Care Excellence. 
†EPIC-CVD was specifically designed as a case-cohort study of cardiovascular disease outcomes, and therefore does not 
contribute to the analysis of non-cardiovascular disease or all-cause mortality outcomes. ‡91 participants had missing 
data in the Copenhagen studies.
Table: Baseline characteristics
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(appendix p 29). Dose­response findings were also 
similar in supplementary analyses that combined study­
specific HRs by deciles of 25(OH)D or according to 
the four 25(OH)D categories (appendix pp 16, 30).
In overall Mendelian randomisation analyses (that is, 
population­averaged estimates across the full range of 
the 25[OH]D concentration distribution), there was no 
association between genetically­predicted 25(OH)D and 
coronary heart disease (odds ratio [OR] 0·98 [95% CI 
0·95–1·01]; p=0·18), stroke (OR 1·01 [0·97–1·05]; 
p=0·61), or all­cause mortality (OR 0·99 [0·95–1·02]; 
p=0·39; figure 2; appendix pp 17, 31). However, there was 
some evidence of an overall inverse association with all­
cause mortality in the Copenhagen studies (OR 0·89 
[0·80–0·99]; p=0·030; appendix p 17). In combined 
analyses within strata, there was strong evidence for an 
inverse association with all­cause mortality in the 
deficient stratum (OR 0·69 [95% CI 0·59–0·80]; 
p<0·0001), and non­significant inverse asso ciations in 
the deficient stratum with coronary heart disease 
(OR 0·89, 95% CI 0·76–1·04, p=0·14) and stroke 
(OR 0·85, 95% CI 0·70–1·02, p=0·09). By contrast, 
estimates for other strata were much closer to the null 
(figure 2). Similar results were observed for supple­
mentary analyses that considered incident stroke 
outcomes only and ischaemic stroke only (appendix p 18), 
and incident coronary heart disease outcomes only 
(appendix p 19). The association in the deficient stratum 
for haemorrhagic stroke was much closer to the null than 
for ischaemic stroke (appendix p 18). In sensitivity 
analyses excluding variants from each gene region in 
turn (appendix p 20), the association with all­cause 
mortality in the deficient stratum was attenuated, but 
remained nominally significant when excluding variants 
in the CYP2R1 gene region from the analysis (OR 0·80 
[95% CI 0·66–0·98]; p=0·027). No attenuation occurred 
when excluding variants from other gene regions. 
Estimates using the pleiotropic genome­wide score are 
presented in the appendix (p 21).
In Mendelian randomisation analyses for cause­
specific mortality in UK Biobank and the Copenhagen 
studies, inverse associations in the deficient stratum 
were evident for cardiovascular mortality (OR 0·69 
[95% CI 0·52–0·92]; p=0·011) and non­cardiovascular 
Figure 1: Observational associations of 25(OH)D concentration with outcomes
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non­cancer mortality (OR 0·68 [0·54–0·85]; p=0·0009; 
figure 3; appendix pp 22, 32). A non­significant inverse 
association was observed for cancer mortality (OR 0·81, 
95% CI 0·65–1·02, p=0·09). Again, overall estimates and 
estimates within other strata were generally null. When 
dividing non­cardiovascular non­cancer mortality into 
more specific mortality categories, the strongest asso­
ciations in the deficient stratum were for diseases of the 
nervous system and the digestive system (appendix p 23).
In Mendelian randomisation analyses for a finer 
stratification of 25(OH)D concentrations, the dose­
response curve for all­cause mortality has a clear threshold 
shape with evidence of an inverse association at 25(OH)D 
concentrations below 40 nmol/L, and null associations 
above 40 nmol/L (figure 4; appendix p 33); there was a 
notable trend in estimates below 40 nmol/L, with stronger 
inverse associations observed at lower 25(OH)D concen­
trations. The shape of dose­response curves for coronary 
heart disease and stroke is not as clear, although larger 
inverse estimates were generally observed for strata with 
low 25(OH)D concentrations.
Discussion
In observational analyses, we found evidence for 
non­linear dose­response relationships of 25(OH)D 
concentrations with coronary heart disease, stroke, and 
mortality outcomes. Population­averaged estimates from 
our genetic analyses suggest that increases in 25(OH)D 
concentrations are unlikely to translate into substantial 
risk reductions for cardio vascular disease or all­cause 
mortality in the population overall. However, genetic 
analyses restricted to indiv iduals with low concentrations 
of 25(OH)D provided strong evidence supporting a causal 
relationship between 25(OH)D concentrations and all­
cause mortality risk up to a threshold of around 40 nmol/L. 
Our results have potential implications for aetiological 
understanding and disease prevention.
Our results challenge the interpretation of null findings 
from previous randomised trials and Mendelian 
randomisation analyses. Most previous trials for cardio­
vascular disease and mortality were done in broadly 
selected groups of the population, so could not reliably 
assess evidence for causality in individuals with low 
concentrations of 25(OH)D. Furthermore, previous 
Mendelian randomisation analyses have not considered 
estimates for strata of the population defined according to 
baseline 25(OH)D concentrations, and hence have not 
considered the shape of the causal relationship between 
25(OH)D concentrations and cardiovascular disease or 
all­cause mortality.
By contrast, our investigation showed inverse asso­
ciations between genetically­predicted 25(OH)D concen­
trations and mortality outcomes that were limited to the 
stratum of the population with low 25(OH)D concen­
trations. This finding suggests that any potential benefit 
of vitamin D supplementation could be restricted to those 
with low concentrations of 25(OH)D. This concept is 
Figure 2: Mendelian randomisation estimates for primary outcomes in overall population and strata of 
residual 25(OH)D concentrations
Estimates (95% CIs) represent odds ratios per 10 nmol/L increase in genetically-predicted concentration of 25(OH)D 
in strata of the population defined by residual concentration of 25(OH)D. 
Coronary heart disease (33 546 events) Estimate (95% CI)
Stroke (18 166 events)

















































Figure 3: Mendelian randomisation estimates for cause-specific mortality in overall population and strata of 
residual 25(OH)D concentrations
Estimates (95% CIs) represent odds ratios per 10 nmol/L increase in genetically-predicted concentration of 25(OH)D 
in strata of the population defined by residual concentration of 25(OH)D. 25(OH)D=25-hydroxyvitamin D.
Cardiovacular mortality (6150 events)
Cancer mortality (12 804 events)
Non-cardiovascular non-cancer mortality (7733 events)
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supported by a previous meta­analysis of vitamin D 
supplementation trials for acute respiratory tract 
infections, which reported stronger evidence of risk 
reduction in those with 25(OH)D concentrations below 
25 nmol/L.26 A general implication of our approach is to 
encourage the use of data and methods that allow 
identification of causal non­linear relationships that 
might otherwise go undetected.
Although our analyses suggest that a 10 nmol/L increase 
in genetically­predicted concentration of 25(OH)D is 
associated with about 30% lower risk of all­cause mortality 
in the deficient stratum (<25 nmol/L), previous Mendelian 
randomisation analyses for other risk factors have 
generally over­estimated the potential quantitative benefit 
compared with real­world inter ventions. For example, 
Mendelian randomisation estimates for low­density 
lipoprotein cholesterol on coronary heart disease risk are 
around 3­times larger than estimates from statin trials 
with a median follow­up of 5 years.27 This finding might 
be because differences in risk factors investigated in 
Mendelian randomisation represent lifelong differences 
in usual levels of the risk factor. In contrast, randomised 
trials typically investigate short­term to medium­term 
interventions in a risk factor. For most diseases, it is 
probable that the benefit of short­term interventions in a 
risk factor will be less substantial than lifelong changes, 
suggesting that it could be challenging for future 
vitamin D supplementation trials to show reductions in 
mortality or morbidity, as the trials would need to be 
targeted at those with low concentrations of 25(OH)D. 
The trials would also need to have adequate power to 
detect small reductions in mortality or morbidity, 
suggesting that both large sample size and extended 
follow­up duration would be required.
There are several potential mechanisms by which 
vitamin D could be protective for cardiovascular mortality, 
including mechanisms linking low vitamin D status with 
hyperparathyroidism and low serum calcium and 
phosphate. Animal studies support a role for vitamin D in 
the regulation of cardiac metalloproteinases and 
fibroblasts, and consequently cardiac ventricular size and 
function.28 Vitamin D is further implicated in endothelial 
cell function, in particular, modulating vascular tone, 
atherosclerosis, and arterial calcification.29,30 There are 
also potential mechanisms implicating vitamin D for 
cancer. For example, vitamin D status affects the 
transcription of genes relating to cell division and 
apoptosis, including for neoplasms, with other effects 
including enhanced DNA repair and immuno­
modulation.31
Our investigation has several strengths. The Mendelian 
randomisation design means that estimates are less 
susceptible to bias from confounding and reverse 
causation than those from conventional observational 
analyses. The availability of individual­level data on 
25(OH)D concentrations, genotypes, and disease 
outcomes on large samples from several independent 
Figure 4: Mendelian randomisation estimates for finer stratification of residual 25(OH)D concentrations at 
5 nmol/L intervals
Estimates (95% CIs) represent odds ratios per 10 nmol/L increase in genetically-predicted vitamin D concentration 
in strata of the population defined by residual concentration of 25(OH)D. Points are plotted on the horizontal axis 
at the central value of each stratum (22·5 nmol/L for the <25 nmol/L stratum, 27·5 nmol/L for the 25–30 nmol/L 
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datasets enabled powerful analysis of people with low 
25(OH)D concentrations. Our focused genetic instru­
ment for vitamin D afforded strong statistical power and 
biological specificity, minimising the potential for bias 
due to horizontal pleiotropy arising from use of variants 
that do not have specific effects on vitamin D pathways. 
The focused score was not associated with major 
cardiovascular risk factors, providing empirical evidence 
that genetic associations with all­cause mortality in the 
deficient stratum were attributable to 25(OH)D 
concentrations.
However, there are also potential limitations. Firstly, the 
Mendelian randomisation assumptions state that the only 
causal pathway from the genetic variants to the outcome 
is via 25(OH)D concentrations. Although our variants are 
all from gene regions specifically relevant to vitamin D 
biology, variants in the CYP24A1 gene region are known 
to associate with circulating calcium levels. Secondly, 
even if the Mendelian randomisation assump tions are 
satisfied, genetic variants could influence 25(OH)D 
concentrations in a different way to dietary supple­
mentation or other clinical interventions. Thirdly, to 
reduce the scope for confounding by ethnicity (population 
stratification), our analyses were limited to middle­aged 
participants of European ancestries. This limitation 
means that our findings might not be applicable to other 
populations. In particular, further analyses are needed to 
assess the potential effect of vitamin D supplementation 
in individuals with dark skin, as this correlates with lower 
25(OH)D concen trations. Fourthly, UK Biobank and 
EPIC­CVD are not fully representative samples of the UK 
and European populations, further limiting the 
applicability of findings. Fifthly, fewer genetic variants 
were available in the Copenhagen studies, limiting 
comparability between datasets; however, although this 
will reduce power for analysis, it should not lead to bias. 
Sixthly, we do not have information from all studies on 
the accuracy of 25(OH)D measurements from external 
quality control pro grammes; however, there was no 
indication that mean 25(OH)D estimates varied by assay 
type, and as any such variation is probably non­differential 
to morbidity and mortality outcomes it would bias the 
results toward the null and therefore cannot explain our 
results. Finally, our primary genetic analyses for cardio­
vascular disease considered both prevalent and incident 
events. Stratification into categories according to residual 
25(OH)D concentration might therefore be affected by 
reverse causation. However, genetic associations with 
disease outcomes within each of the strata will not be 
affected by reverse causation, as genotype is fixed from 
conception. 
In conclusion, we found genetic evidence to suggest a 
causal relationship between 25(OH)D concentrations and 
mortality in individuals with low vitamin D status. Our 
results have implications for the interpretation and design 
of vitamin D supplementation trials, and potential disease 
prevention strategies.
For the steering committee 
data from the Vitamin D 
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